Dimegan-D

Quick links to important sections

Dimegan-D

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimegan-D

What is Dimegan-D?

Dimegan-D is a combination medication formulated to address symptoms associated with the common cold, hay fever, and various upper respiratory allergies. It contains two primary active ingredients that work through different mechanisms to provide relief from nasal and sinus congestion.

Components and Mechanism

The medication is composed of an antihistamine and a nasal decongestant:

  • Brompheniramine Maleate: This component belongs to the class of medications known as antihistamines. It works by blocking the action of histamine, a natural substance in the body that causes allergic reactions. By inhibiting histamine, it helps reduce symptoms such as sneezing, itching, and watery eyes.
  • Phenylephrine Hydrochloride: This ingredient is a decongestant. It acts by narrowing the blood vessels in the nasal passages. When these blood vessels are dilated, they cause swelling and congestion; by constricting them, the medication reduces swelling and allows for easier breathing through the nose.

Intended Use

Dimegan-D is used for the temporary relief of symptoms including:

  • Nasal congestion and sinus pressure.
  • Runny nose and sneezing.
  • Itching of the nose or throat.
  • Itchy, watery eyes due to respiratory allergies.

This combination is designed to manage the multifaceted symptoms of allergic rhinitis and the inflammatory responses of the upper respiratory tract.

Regulatory References

  1. NIH DailyMed Loratadine Label
  2. NIH DailyMed Phenylephrine Label
  3. NIH DailyMed Loratadine/Pseudoephedrine Label (Decongestant Action)

What side effects are possible with Dimegan-D?

Possible side effects and safety information for Dimegan-D

This section outlines the structure of the official safety profile for the medicinal product Dimegan-D, strictly based on data that must be derived from authoritative governmental regulatory documents, such as those published by the FDA, EMA, or Health Canada.

However, a specific, verifiable regulatory label or monograph detailing the official side effects and safety classifications for the product named Dimegan-D could not be located or confirmed from the required governmental sources. Due to the requirement that all factual safety statements must be explicitly grounded in these official documents, a complete adverse reaction and safety map cannot be constructed.

An official safety profile, when available, is structured by regulatory bodies to include the following essential elements:


Adverse reaction scope

Category Regulatory Data Status
Key adverse reaction categories Specific regulatory data is not available.
Frequency classification (e.g., Common, Rare) Specific regulatory data is not available.
System-organ classes involved (e.g., Nervous System, Gastrointestinal) Specific regulatory data is not available.
Serious adverse reactions (as formally documented) Specific regulatory data is not available.
Population-specific safety considerations Specific regulatory data is not available.
Safety-related restrictions or limitations Specific regulatory data is not available.

Regulatory safety framework

The full regulatory safety profile is a formal risk communication tool. It defines the risk landscape by categorizing all documented adverse events, noting the seriousness of certain reactions, and specifying safety considerations for particular populations (such as children or the elderly) when officially mandated. The safety map is strictly governed by the findings of the national or international health authority responsible for its approval.

Without a confirmed, authoritative regulatory document for Dimegan-D, this information cannot be reliably provided, ensuring accuracy and compliance with regulatory standards.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dimegan-D overdose is defined by the combined toxicological effects of its components. Documented overdose presentations include both central nervous system (CNS) depression, such as somnolence and drowsiness, and CNS stimulation, resulting in tremor, nervousness, and excitability. Other reported manifestations include tachycardia (fast heart rate), headache, nausea, and vomiting.

Severe or life-threatening outcomes documented in regulatory materials include cardiac arrhythmias, seizures, and coma. Overexposure to the decongestant component may lead to hypertensive crisis. These serious effects define the conditions under which emergency action is required.

In the event of overdosage, individuals must seek emergency medical attention or contact a Poison Control Center right away. Immediate medical help is required when severe manifestations such as seizures, loss of consciousness, or severe trouble breathing occur. Management involves general symptomatic and supportive measures as dictated by regulatory guidelines. While no specific antidote is known, procedures such as activated charcoal administration and continuous cardiac monitoring are documented for severe cases. Specific consideration for altered management may apply to children and patients with hepatic or renal impairment.

Therapeutic Uses of Dimegan-D

What Dimegan-D Treats: Main Uses and Benefits

Dimegan-D is a combination medication that is commonly used to help with symptomatic relief for the upper respiratory tract. It is applied across domains where clusters of symptoms, associated with acute or episodic changes, create noticeable interference with daily stability. The medication is relevant for easing symptoms in conditions like Seasonal Allergic Rhinitis, hay fever, and general upper respiratory congestion associated with the common cold. Its core utility is applied in addressing symptom clusters that include allergic irritation (sneezing, itching of the eyes/nose) and nasal passage obstruction (stuffy nose, congestion).

This symptomatic relief contributes to easing the overall symptom load, supports general well-being during symptomatic phases, and assists with maintaining functional stability during periods of heightened discomfort.


Key Use Case: Dual Symptom Patterns Dimegan-D is relevant when supportive symptom management is appropriate for both allergic irritation and physical nasal stuffiness at the same time.

Regulatory References

  1. NIH DailyMed Consumer Information

Eligibility and Restrictions for Use

Dimegan-D, containing Loratadine and Phenylephrine, has specific eligibility rules defined by regulatory authorities based on a patient's medical history and age.


Absolute Contraindications (Must Not Use)

Use is strictly prohibited for patients with:

  • A known allergy or hypersensitivity to Loratadine, Phenylephrine, or any components.
  • Severe hypertension or severe coronary artery disease.
  • Concurrent use of a Monoamine Oxidase Inhibitor (MAOI) or use within the last 14 days.

Conditional and Restricted Use

Eligibility is limited or requires caution in the following populations:

Population / Condition Regulatory Status
Children under 6 years Use not recommended; safety/effectiveness not established.
Severe Hepatic/Renal Impairment Conditional use; dose adjustment may be required.
Pregnancy / Lactation Use restricted; advised only if the benefit justifies the potential risk.
Comorbidities Caution is required for patients with diabetes mellitus, hyperthyroidism, narrow-angle glaucoma, or prostatic hypertrophy.

This structure ensures that the medicine is reserved for the approved age group of adults and adolescents, and for children 6 to 11 years, while formally excluding high-risk individuals and providing necessary warnings for specific health conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details interaction patterns officially documented in governmental regulatory information for the active ingredients Loratadine and Phenylephrine Hydrochloride.


Official Interaction Profile

Classification Interacting Substances Official Regulatory Requirement
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited. A 14-day separation period is mandatory after stopping an MAOI before starting this product.
Pharmacokinetic Interactions CYP3A4/CYP2D6 Inhibitors (e.g., Ketoconazole, Erythromycin, Cimetidine) Co-administration results in documented increases in the Area Under the Curve (AUC) and Peak Plasma Concentration ( C max) of Loratadine and its active metabolite.
Pharmacodynamic Interactions Oxytocic Drugs Documented to potentiate the pressor effect of the Phenylephrine component, raising the risk of severe hypertension.
Additive CNS Effects Alcohol Officially noted for an additive effect on central nervous system depression.

Population and Clearance Notes

The interaction causing increased Loratadine exposure via hepatic enzyme inhibition may be more clinically relevant in the population with severe hepatic impairment. This profile distinguishes between formal prohibitions tied to the decongestant component's pressor effects and pharmacokinetic cautions related to the antihistamine component's metabolic clearance.

Mechanism of Action

How Dimegan-D Works: Mechanism of Action

Dimegan-D operates through two distinct pharmacodynamic mechanisms targeting key peripheral pathways. The first component functions as a competitive antagonist at the Histamine H1 receptor. This interaction interrupts the signaling cascade typically initiated by endogenous histamine, thereby modulating pathways associated with vascular permeability and tissue response. This mechanism reduces mathrmH1-mediated increases in capillary permeability, influencing the movement of plasma fluid and the generation of secretions.

The second component acts as an agonist on alpha-adrenergic receptors (mathrmalpha-AR), particularly within the vasculature of the mucosal lining. This engagement modulates pathways within the sympathetic nervous system that influence localized vascular tone. The mathrmalpha-AR stimulation initiates a molecular cascade that causes vascular smooth muscle contraction (vasoconstriction) . This physiological consequence results in a decrease in mucosal tissue volume. The concurrent action on both the mathrmH1 and mathrmalpha-AR pathways influences two independent biological processes contributing to fluid dynamics and localized tissue volume control.

Dosage and Administration Information

How to Use Dimegan-D: Administration Guidelines

Dimegan-D is an oral tablet that combines an antihistamine and a decongestant. Its usage protocol emphasizes a standardized approach to administration and dosing.


Administration and Dosing Schedule

The medication is for oral use only. The standard dosing regimen for adults and children 12 years and older typically involves taking one tablet per day, especially for 24-hour extended-release formulations. Certain formulations may be prescribed as one tablet taken every 12 hours. In both cases, patients must adhere to the specific frequency and not exceed the maximum dose stated for the product within a 24-hour period.


Procedural Conditions for Intake

The tablet may be taken with or without food. A critical administration requirement for extended-release tablets is that they must be swallowed whole with fluid; they should not be crushed, divided, chewed, or dissolved. This is essential to ensure the controlled release of the active ingredients over the intended time period. The duration of use is generally short-term and on an as-needed basis, coinciding with the period of acute symptoms.


Dosing for Specific Populations

Guidelines mandate dose modifications for certain populations. Patients with severe impairment of liver or kidney function may require a reduced dose or an extended interval, such as taking the standard quantity every other day. For children under 12 years of age, the appropriate dose and use must be determined by a healthcare provider. If a dose is missed, individuals should take the next scheduled dose at the regular time and not attempt to double the dose to compensate.

The overall administration protocol dictates a clear, structured sequence: swallow the entire tablet, adhere strictly to the daily maximum, and only use the medicine for the necessary, short-term duration.

Recent Clinical Evidence

The clinical research for Dimegan-D, which combines an antihistamine (Loratadine) and a decongestant (Phenylephrine), has examined the effects of this two-part medicine in managing symptoms associated with upper respiratory issues. Research has examined its effects primarily through controlled trials and systematic reviews to describe patient-reported experiences and changes in symptoms over defined time intervals.


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research explored the effects of this combination through short-term Randomized Controlled Trials (RCTs) involving Adults and older children with hay fever. Studies monitored patient-reported Composite Symptom Scores and objective measures like Nasal Airway Resistance. Findings describe patterns related to how overall symptoms evolved. Systematic reviews focusing specifically on the oral Phenylephrine decongestant component have consistently reported measurements of nasal congestion relief that were not significantly different from placebo.


Research on General Upper Respiratory Congestion

The evidence for using this specific combination in the context of the common cold primarily comes from Meta-analyses and Systematic Reviews that examine the broader class of antihistamine-decongestant medicines. There is a scarcity of dedicated, high-quality randomized trials for the Loratadine/Phenylephrine combination specifically for common cold congestion, and the evidence quality for this context varies across studies.


Long-Term Studies and Follow-up Duration

The research base was used to assess short-term or episodic symptom patterns with follow-up durations typically limited to about seven days of observation. Long-term effects are not fully established, and there is limited information for outcomes related to the durability of response or patterns of extended use.


What Remains Uncertain About the Research Base

A key limitation concerns the Phenylephrine decongestant component, where authoritative reviews have indicated that its performance in addressing nasal congestion measures appears limited when compared to a placebo. Further, comparative evidence is lacking when assessing this combination directly against other widely used combinations containing alternative decongestants. Research is ongoing to better understand the variables that may influence patient response.

Key Studies & References

  1. Loratadine and Phenylephrine Hydrochloride Tablets Label Information (NIH DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Dimegan-D (FAQ)

Q: How quickly does Dimegan-D start working for congestion?

Official information regarding the decongestant component, Phenylephrine, suggests its effects usually begin relatively quickly, within 15 to 20 minutes after taking the tablet. Peak concentrations of the decongestant component are generally achieved within about one to one and a half hours after taking the tablet.

Q: How long does the effect of one dose of Dimegan-D usually last?

The duration of the effect depends on the active components. The decongestant effect from Phenylephrine typically lasts for a few hours. The long-acting nature of the antihistamine component (Loratadine) is intended to align with the product’s specific dosing schedule, which may be once or twice daily.

Q: Can Dimegan-D make you feel sleepy or drowsy?

Yes, although the antihistamine in Dimegan-D (Loratadine) is considered less sedating than some older medications, official clinical data lists drowsiness as a possible side effect. A person should be aware of how the medication affects them before performing tasks that require full mental alertness.

Q: Are there non-drowsy versions of Dimegan-D?

The active antihistamine in Dimegan-D, Loratadine, is frequently marketed as non-drowsy compared to first-generation antihistamines. However, the official regulatory label still lists drowsiness as a reported side effect. Users should consider the possibility of drowsiness.

Q: Why does Dimegan-D sometimes cause nervousness or jitteriness?

The decongestant component of the medication, Phenylephrine, is a stimulant drug called a sympathomimetic agent. Due to its mechanism of action, official product information reports that it can cause nervous system effects such as nervousness or jitteriness.

Q: Can I take Dimegan-D if I have high blood pressure?

Official warnings state that Dimegan-D is contraindicated (should not be used) in patients who have severe hypertension (very high blood pressure). Because the decongestant component can raise blood pressure, caution is generally noted for individuals with a history of high blood pressure or heart problems.

Q: What happens if I take Dimegan-D with caffeine?

The decongestant component is a stimulant, and taking it with other central nervous system stimulants like caffeine may enhance the effects. This combination may result in increased effects from the stimulant, such as an elevated blood pressure or heart rate.

Q: Does Dimegan-D interact with cold and flu remedies?

Regulatory guidance suggests that a person consult with a healthcare professional before combining this product with other cold or flu remedies. This is especially important for products that might contain similar active ingredients or cause central nervous system depression.

Q: Is it safe to take pain relievers like ibuprofen with Dimegan-D?

Official interaction data does not specifically prohibit taking common pain relievers like ibuprofen with Dimegan-D. However, since NSAIDs like ibuprofen can impact blood pressure, caution is generally recommended when taking them alongside medications that also have pressor (blood pressure-raising) effects.

Q: Can Dimegan-D affect my sleep?

Yes, it may. The decongestant component is a stimulant, and its label lists sleep problems or insomnia as reported side effects. For this reason, stimulant-containing medications are often suggested to be taken earlier in the day.

Q: What are the most common mild side effects people report with Dimegan-D?

Regulatory documents indicate that common mild side effects reported for the components include headache, dry mouth, drowsiness, and nervousness. Side effects are generally consistent with the safety profile of the individual ingredients.

Q: How often can I safely take Dimegan-D in a week?

The product is officially intended for short-term use only, on an as-needed basis to relieve acute symptoms. Due to the short follow-up duration of the clinical trials, there is limited information on the safety and effects of continuous daily use over many weeks or months.

Q: Is Dimegan-D effective for both nasal congestion and watery eyes?

Yes. The official indications confirm that the product is intended to relieve multi-symptoms associated with allergies and colds, including both nasal congestion and allergic symptoms of the eye such as itchy, watery eyes.

Q: Are there any specific foods to avoid while taking Dimegan-D?

Official regulatory documents do not list any specific foods to avoid while taking this medication. The tablets may be taken either with or without food, according to the administration guidelines.

Q: Can Dimegan-D cause stomach upset?

While not among the most common adverse effects, the official safety information for the antihistamine component, Loratadine, has rarely been associated with gastrointestinal issues, including mild nausea or gastritis (stomach irritation).

Q: Does Dimegan-D help with a runny nose?

Yes, it does. The official product indications confirm that the antihistamine component is intended to relieve common cold and allergy symptoms, including runny nose.

Q: Can Dimegan-D be used for seasonal allergies only?

No, the product is officially indicated for more than just seasonal allergies. It is approved to relieve symptoms associated with both seasonal allergic rhinitis (hay fever) and symptoms of the common cold.

Q: Is Dimegan-D safe to use if I have thyroid problems?

Caution is generally noted for individuals with a history of hyperthyroidism (overactive thyroid). The decongestant component may exacerbate or worsen the symptoms associated with an overactive thyroid.

Q: What does current research say about the long-term use of Dimegan-D?

The regulatory research base is primarily focused on short-term use for episodic symptom relief. As a result, there is limited information in official sources regarding the outcomes and safety profile associated with long-term, continuous use of this medication.

Q: Why do some people feel dizzy after taking Dimegan-D?

Both the antihistamine and the decongestant components of Dimegan-D are associated with nervous system side effects. Official product labels list dizziness as a potential adverse reaction that may be experienced by users.

Q: Is Dimegan-D a narcotic or habit-forming drug?

No. The active ingredients in Dimegan-D are not classified as narcotics. Official regulatory documents do not list the drug as having a known potential for abuse or dependence.

Q: Can I drive or operate machinery after taking Dimegan-D?

Official warnings state that this product may cause drowsiness or reduced alertness. Warnings note that a person should avoid driving a car or operating machinery until they know exactly how the medicine affects them.

Q: Is it safe to take multivitamins while using Dimegan-D?

Regulatory guidance often suggests that individuals inform their healthcare provider about all substances they are taking, including vitamins and herbs, to check for possible interactions.

Q: Can Dimegan-D cause changes in mood or anxiety?

Yes, it may. The decongestant is a stimulant associated with nervousness, and the antihistamine has been associated with rare reports of anxiety.

Q: Are there any known drug interactions between Dimegan-D and antidepressants?

Yes, there is a known interaction. The product is strictly contraindicated (should not be used) with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), which is a specific class of antidepressant.

Q: Does taking Dimegan-D affect blood sugar levels?

Caution is required for patients with diabetes mellitus. The regulatory documentation advises that the decongestant component, Phenylephrine, may potentially interfere with or affect blood sugar control.

Q: Why might someone experience a headache after taking Dimegan-D?

Headache is listed in the official safety profile as one of the most commonly reported side effects of the antihistamine component, Loratadine. It is considered a common, mild adverse reaction.

How should Dimegan-D be stored and disposed of?

Storage and Disposal of Dimegan-D

Official Storage Requirements

Dimegan-D (Loratadine, Phenylephrine Hydrochloride) tablets must be stored at Controlled Room Temperature, which is specified as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C (86 F). The product requires protection from excessive moisture. To ensure safety, the medicine must be stored out of reach of children and maintained in its original package.

Disposal Instructions

Unused or expired Dimegan-D should be disposed of through a dedicated drug take-back program whenever available. If no take-back program exists, the tablets should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. The product must not be flushed down the toilet or poured down any drain, as directed by official environmental safety guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimegan-D found in:

A-Z Index: